This is the authors' abstract. We don't add key points for this paper.
Recently the FDA conducted a risk investigation and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy? Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: